Angiogenesis in cardiovascular disease: current status and therapeutic potential.
Therapeutic angiogenesis, in the form of growth factor protein administration or gene therapy, has emerged as a new method of treatment for patients with severe, inoperable coronary artery disease. Improved myocardial perfusion and function after the administration of angiogenic growth factors has been demonstrated in animal models of chronic myocardial ischaemia. Recently, preliminary clinical trials using growth factor proteins or genes encoding these angiogenic factors have demonstrated clinical and other objective evidence of relevant angiogenesis. Thus, therapeutic angiogenesis has the potential to extend treatment options to patients who are not optimal candidates for conventional methods of myocardial revascularisation.
Sellke
F W
FW
Beth Israel Deaconess Medical Center, Division of Cardiothoracic Surgery, Harvard Medical School, Boston, Massachusetts 02215, USA. fsellke@bidmc.harvard.edu
Simons
M
M
D043925:Angiogenesis Inducing Agents / Q000627:therapeutic use*; D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003331:Coronary Vessels / Q000378:metabolism*; D015316:Genetic Therapy; D006133:Growth Substances / Q000627:therapeutic use*; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy*; D009206:Myocardium / Q000378:metabolism*
D043925:Angiogenesis Inducing Agents; D006133:Growth Substances